USPTO Examiner WINSTON RANDALL O - Art Unit 1655

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17138221Micro-fog anti pathogenic composition and method of preparationDecember 2020December 2022Abandon2421YesNo
17135152FUNCTIONAL TEA CONTAINING BENEFICIAL INGREDIENTS FOR THE HUMAN BODYDecember 2020December 2022Abandon2411NoNo
17255604PHARMACEUTICAL COMPOSITION FOR ALLEVIATING EYE FATIGUE, CONTAINING, AS ACTIVE INGREDIENTS, LUTEOLIN-7-O-DIGLUCURONIDE AND APIGENIN-7-O-DIGLUCURONIDE ISOLATED FROM PERILLA FRUTESCENS (L.) BRITTON VAR. ACUTA (THUNB.) KUDO LEAF EXTRACTDecember 2020December 2022Abandon2410YesNo
17123929PROCESS FOR PRODUCING AN EXTRACT CONTAINING TETRAHYDROCANNABINOL AND CANNABIDIOL FROM CANNABIS PLANT MATERIAL, AND CANNABIS EXTRACTSDecember 2020December 2021Abandon1110NoNo
16972066COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITYDecember 2020November 2024Abandon4741YesNo
17100750METHOD FOR ISOLATION OF MAO INHIBITORS FROM TEQUILA OR OTHER DISTILLED AGAVE FERMENTATION PRODUCTSNovember 2020May 2023Abandon2920NoNo
17055822EUTECTIC EXTRACT FORMATION AND PURIFICATIONNovember 2020June 2023Allow3111NoNo
17089989METHOD TO PREPARE A THERAPEUTIC BALMNovember 2020August 2022Allow2110NoNo
17078406Botanical Synergistic Activated/Native and Equivalents ThereofOctober 2020September 2024Abandon4740NoNo
17075868COMPOUND ESSENTIAL OIL COMPOSITION AND USE THEREOF FOR IMPROVING COGNITION, SLEEP AND MOODOctober 2020October 2022Abandon2310NoNo
17072246COMPOSITIONS CONTAINING KRATOM COMPOUNDSOctober 2020February 2024Abandon4021NoNo
17026801Pharmaceutical Composition Based on Plant Raw MaterialsSeptember 2020June 2021Allow810YesNo
17027006PROMOTING SLEEP USING AT1 RECEPTOR BLOCKERSSeptember 2020May 2022Allow2010NoNo
15733622Preparation Method of Agrocybe Aegerita Extract and its use in Preparing Medicine for Lowering Uric AcidSeptember 2020May 2023Abandon3221NoNo
17002169Method for the Stimulation of Human Immune CellsAugust 2020October 2022Allow2511NoNo
17001440ANTI-MICROBIAL AMALGAMATE OF NON-TOXIC NATIVE COMPOSITIONAugust 2020April 2024Abandon4331NoNo
16986469EXTRACTS OF HALIMIONE PORTULACOIDES AND THEIR APPLICATIONAugust 2020August 2022Abandon2501NoNo
16983975HONEY-BASED GEL COMPOSITIONAugust 2020March 2024Abandon4320NoNo
16965754COMPOSITION FOR PREVENTING OR TREATING DRY EYE SYNDROME, CONTAINING AUCUBA JAPONICA EXTRACTJuly 2020November 2023Allow4031YesNo
16946721THERAPEUTIC HERBAL COMPOSITIONS FOR IMPROVING JOINT HEALTHJuly 2020March 2022Allow2131YesNo
16911716PROCESS FOR PRODUCING AN EXTRACT CONTAINING TETRAHYDROCANNABINOL AND CANNABIDIOL FROM CANNABIS PLANT MATERIAL, AND CANNABIS EXTRACTSJune 2020June 2022Abandon2310NoNo
16906844COMPOSITION FOR ALLEVIATING SKIN INFLAMMATION CAUSED BY YELLOW DUST AND FINE PARTICULATE, COMPRISING NATURAL PLANT EXTRACTJune 2020August 2022Abandon2610NoNo
16898472Nutraceuticals for Reducing Myeloid Suppressor CellsJune 2020March 2023Abandon3320NoNo
16897378COMPOSITION FOR RELIEVING STRESS AND ENHANCING IMMUNITY AND PREPARATION METHOD THEREOFJune 2020December 2022Abandon3011NoNo
16858254THERAPEUTIC COMPOSITION INCLUDING CARBONATED SOLUTIONApril 2020September 2023Allow4040NoNo
16856241COMPOSITIONS OF MARINE BOTANICALS TO PROVIDE NUTRITION TO AGING AND ENVIRONMENTALLY DAMAGED SKINApril 2020April 2022Allow2310NoNo
16854349OLIVE COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONSApril 2020February 2023Abandon3411NoNo
16851637METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSISApril 2020January 2024Abandon4521NoNo
16834351ADMINISTERING COMPOSITIONS FOR IMPROVED IMMUNE SYSTEM FUNCTIONINGMarch 2020January 2022Allow2210NoNo
16873368RaeLinn - JKLMarch 2020November 2021Abandon1910NoNo
16821421THERAPEUTIC COMPOSITION INCLUDING CARBONATED SOLUTIONMarch 2020August 2023Allow4131NoNo
16816214COMPOSITIONS AND METHODS FOR TREATMENT OF ALCOHOL INDUCED LIVER INJURYMarch 2020November 2022Abandon3211NoNo
16806000MATERIALS AND METHODS FOR IMPROVING IMMUNE RESPONSES AND SKIN AND/OR MUCOSAL BARRIER FUNCTIONSMarch 2020September 2022Allow3011NoNo
16726323SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOFDecember 2019February 2022Abandon2610NoNo
16725246SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOFDecember 2019February 2022Allow2610NoNo
16725608COMPOSITION, CONTAINING QUISQUALIS INDICA EXTRACT, FOR PREVENTING OR TREATING PROSTATIC HYPERPLASIADecember 2019June 2023Allow4130NoNo
16725125SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOFDecember 2019August 2022Allow3120NoNo
16722292SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOFDecember 2019May 2022Abandon2811NoNo
16610859METHODS OF TREATING SYSTEMIC GRAFT-VERSUS-HOST DISEASE WITH EXTRACELLULAR VESICLESNovember 2019August 2022Allow3321NoNo
16659591SEASONED LAVER INCLUDING HEMP OIL AND MANUFACTURING METHOD THEREOFOctober 2019November 2021Abandon2501NoNo
16653647METHODS AND COMPOSITIONS FOR TREATING JOINT DISEASEOctober 2019January 2022Abandon2720NoNo
16550066EDIBLE CRICKET COMPOSITION FOR PREVENTING HAIR LOSS, IMPROVING HAIR FOLLICLE, AND PROMOTING HAIR REGROWTHAugust 2019January 2022Abandon2911NoNo
16516622PLANT EXTRACT CONTAINING DIKETOPIPERAZINE AND METHOD FOR PRODUCING SAMEJuly 2019April 2022Allow3311NoNo
16507838Protective Effects of Oil Palm Composition on Alzheimer's DiseaseJuly 2019February 2022Abandon3130NoNo
16436581Method of Making a Dietary SupplementJune 2019February 2022Abandon3220NoNo
16433169ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATIONJune 2019February 2021Allow2110NoNo
16465984FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTSMay 2019September 2021Allow2711YesNo
16461786NOVEL FORMULATIONS AND USES THEREFORMay 2019March 2021Abandon2201NoNo
16407827Oat Fractions With Enhanced Avenanthramide Concentration and Methods of MakingMay 2019December 2021Allow3221YesYes
16345401INHIBITOR FOR COGNITIVE FUNCTION DECLINEApril 2019April 2021Allow2410NoNo
16392830EXCIPIENT SYSTEM FOR TOPICAL DELIVERY OF PHARMACEUTICAL AGENTSApril 2019January 2022Abandon3221NoNo
16289198PORE MINIMIZERFebruary 2019February 2021Allow2410NoNo
16246411ENCAPSULATED CANNABINOID FORMULATIONS FOR TRANSDERMAL DELIVERYJanuary 2019March 2020Allow1411NoNo
16246400ENCAPSULATED CANNABINOID FORMULATIONS FOR ORAL DELIVERYJanuary 2019March 2020Allow1411NoNo
16244719NOOTROPIC AND SKIN SUPPLEMENT COMPOSITIONS AND METHOD TO PROVIDE A TAILORED SUPPLEMENTJanuary 2019May 2022Abandon4021NoNo
16221167Cream and Oil for Facial RejuvenationDecember 2018December 2020Allow2401NoNo
16210267WATER-SOLUBLE CANNABINOIDS AND METHODS OF MAKING SAMEDecember 2018December 2021Allow3721NoNo
16200344ANTI-CANCER DRUG COMPOSITION INCLUDING GANODERMA EXTRACT AND AMPHOTERICIN BNovember 2018June 2021Abandon3111NoNo
16099860HOP PROCESSED PRODUCTNovember 2018August 2022Abandon4531YesNo
16183022SOLID AGAVE SYRUP COMPOSITIONSNovember 2018April 2021Allow2910NoNo
16178850SIMMONDSIN FORMULATIONNovember 2018March 2022Allow4121NoNo
16171297COMPOSITIONS AND METHODS OF BDNF ACTIVATIONOctober 2018August 2022Allow4632YesNo
16095447PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD COMPRISING OAT EXTRACT AVENANTHRAMIDE C OR DERIVATIVE THEREOF AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASEOctober 2018August 2021Allow3411YesNo
16158399USES OF MENTHA ESSENTIAL OILOctober 2018September 2021Abandon3621NoNo
16092374USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIAOctober 2018April 2023Allow5431NoYes
16133760METHOD FOR PREPARING TEA LEAF EXTRACTSeptember 2018March 2021Allow3011NoNo
16133033PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS COMPRISING OAT EXTRACT AS AN ACTIVE INGREDIENTSeptember 2018April 2021Allow3111NoNo
16111527Method of Using Composition Containing Hovenia Dulcis Thunb. Extract as Active Ingredient for Prevention and Treatment of Bone DiseasesAugust 2018September 2021Allow3621NoNo
16110371COMPOSITION FOR PROTECTING CELL FROM OXIDATIVE STRESS COMPRISING GREEN TEA EXTRACT WHICH HAS MODIFIED AMOUNTS OF INGREDIENTSAugust 2018May 2021Allow3321NoNo
16105511COMPOSITION FOR TREATMENT OR PREVENTION OF LUNG CANCER AND A METHOD THEREFOREAugust 2018August 2022Abandon4840NoNo
16100956METHOD FOR CELL REJUVENATION USING ROSA ROXBURGHII FRUIT EXTRACTSAugust 2018February 2022Abandon4240NoNo
15998364Acid-relief agent and method of preparationAugust 2018January 2021Abandon2911NoNo
16058484TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOFAugust 2018February 2021Allow3011NoNo
16059002METHOD FOR REDUCTION, SUPPRESSION, OR ELIMINATION OF ANXIETY OR MARIJUANA/CANNABIS EFFECTS AND RELATED MARIJUANA/CANNABIS PRODUCT BY PROCESSAugust 2018March 2023Abandon5541NoNo
16076092INHIBITOR OF INFLAMMASOME ACTIVATIONAugust 2018February 2022Allow4331YesNo
16075795Composition of Plant Extracts That Increase D�derlein's Bacilli, Used for the Treatment of Sexually Transmitted Diseases (STD) and the Human Papillomavirus (HPV), Having an Aphrodisiac EffectAugust 2018January 2021Abandon2910NoNo
16073813NICOTINE FREE HERBAL COMPOSITION FOR SMOKING DE-ADDICTION AND TREATMENT OF SIDE-EFFECTS AND/OR AILMENTS FROM SMOKINGJuly 2018March 2021Allow3120YesNo
16048023CANNABINOID COMPOSITION HAVING AN OPTIMIZED FATTY ACID EXCIPIENT PROFILEJuly 2018December 2021Abandon4121NoNo
16070899COMPOSITE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CRUDE DRUG-STABILIZING DRIED POWDERJuly 2018August 2021Abandon3721NoNo
16037836COMPOSITION FOR TREATING DIABETIC DISEASEJuly 2018January 2022Abandon4230NoNo
16070391BIOACTIVE COMPOSITIONS FROM GINSENG PLANT (PANAX SPP.) AND METHODS FOR THEIR PRODUCTION AND USEJuly 2018June 2021Allow3521NoNo
16070006FORMULATION FOR TREATING MIGRAINEJuly 2018January 2021Abandon3111NoNo
16069265ACTIVE INGREDIENT OBTAINED FROM OPHIOPOGON JAPONICUS FOR THE TREATMENT OF ATOPIC DERMATITISJuly 2018December 2021Allow4131NoNo
16030462POWDER FORMULATION HAVING HYPOGLYCEMIC AND HYPOLIPIDEMIC FUNCTIONS AND METHOD FOR PREPARING THE SAMEJuly 2018November 2020Allow2911NoNo
16068769STABLE PALM INFLORESCENCE SAP POWDER COMPOSITIONS AND ITS PHARMACOLOGICAL EFFECTSJuly 2018July 2021Allow3611NoNo
16068535BICONTINUOUS MICROEMULSIONS AND METHODS OF USE THEREOFJuly 2018February 2022Abandon4331NoNo
16068408Agent for Activating Astrocyte Glucose MetabolismJuly 2018December 2020Allow2911NoNo
16068213FOOD COMPOSITION FOR PREVENTING AND ALLEVIATING FEMALE MENOPAUSE SYMPTOMS CONTAINING GRAPE SEED EXTRACT, VALERIAN EXTRACT AND SAFFLOWER SEED EXTRACTJuly 2018August 2020Abandon2501NoNo
16023327BOYSENBERRY COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOFJune 2018July 2023Abandon6051NoNo
16067376PROCESS FOR PREPARING A CRASSOCEPHALUM CREPIDIOIDES EXTRACT, EXTRACT PREPARED THEREBY AND USE OF THE EXTRACTJune 2018January 2021Allow3120NoNo
16065447SKIN CLEANSING COMPOSITIONJune 2018November 2020Allow2911NoNo
16010816SKIN MASSAGE GEL AND METHOD OF PREPARING THE SAMEJune 2018February 2020Allow2011NoNo
16010719COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING A URINARY TRACT INFECTIONJune 2018January 2021Abandon3011NoNo
16010226COMPOSITION CONTAINING MELDONIUM DIHYDRATE FOR THE PREVENTION AND TREATMENT OF NEURODEGNERATIVE DISEASESJune 2018December 2021Abandon4211NoNo
16007143Cosmetic Compositions and Methods for Their Use in Firming SkinJune 2018March 2022Allow4541YesYes
16007524COMPOSITIONS AND METHODS FOR ENHANCING HYPERTHERMIA THERAPYJune 2018July 2020Allow2530NoNo
16003875TOPICAL SKINCARE COMPOSITIONS COMPRISING CENTELLA ASIATICA SELECTED TRITERPENESJune 2018December 2020Allow3021NoNo
16060386TOPICAL SKIN CARE COMPOSITIONS COMPRISING MYRSINE AFRICANA EXTRACTSJune 2018August 2021Abandon3821NoNo
15995128USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISORDERS AND VIRAL DISEASESJune 2018April 2021Abandon3412NoNo
15994554COMPOSITIONS AND METHODS FOR TREATING VARICOSE VEINSMay 2018April 2022Abandon4631NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WINSTON, RANDALL O.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
7
(77.8%)
Examiner Reversed
2
(22.2%)
Reversal Percentile
35.7%
Lower than average

What This Means

With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
81
Allowed After Appeal Filing
31
(38.3%)
Not Allowed After Appeal Filing
50
(61.7%)
Filing Benefit Percentile
63.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 38.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner WINSTON, RANDALL O - Prosecution Strategy Guide

Executive Summary

Examiner WINSTON, RANDALL O works in Art Unit 1655 and has examined 781 patent applications in our dataset. With an allowance rate of 55.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner WINSTON, RANDALL O's allowance rate of 55.3% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WINSTON, RANDALL O receive 1.81 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WINSTON, RANDALL O is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +38.7% benefit to allowance rate for applications examined by WINSTON, RANDALL O. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.5% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 144.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 89% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 83.9% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 68.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.6% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.